BR112021022876A2 - Método para descolonizar candida auris de uma área anatômica de um sujeito - Google Patents
Método para descolonizar candida auris de uma área anatômica de um sujeitoInfo
- Publication number
- BR112021022876A2 BR112021022876A2 BR112021022876A BR112021022876A BR112021022876A2 BR 112021022876 A2 BR112021022876 A2 BR 112021022876A2 BR 112021022876 A BR112021022876 A BR 112021022876A BR 112021022876 A BR112021022876 A BR 112021022876A BR 112021022876 A2 BR112021022876 A2 BR 112021022876A2
- Authority
- BR
- Brazil
- Prior art keywords
- decolonize
- candida auris
- subject
- anatomical area
- enfumafungin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849019P | 2019-05-16 | 2019-05-16 | |
| PCT/US2020/032547 WO2020232037A1 (en) | 2019-05-16 | 2020-05-12 | Antifungal agents, like ibrexafungerp for candida auris decolonization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022876A2 true BR112021022876A2 (pt) | 2022-04-12 |
Family
ID=70861571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022876A BR112021022876A2 (pt) | 2019-05-16 | 2020-05-12 | Método para descolonizar candida auris de uma área anatômica de um sujeito |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220211684A1 (https=) |
| EP (1) | EP3968986A1 (https=) |
| JP (2) | JP7770191B2 (https=) |
| KR (1) | KR20220009416A (https=) |
| CN (1) | CN113905733A (https=) |
| AU (1) | AU2020276595B2 (https=) |
| BR (1) | BR112021022876A2 (https=) |
| CA (1) | CA3140637A1 (https=) |
| EA (1) | EA202193146A1 (https=) |
| IL (1) | IL288165B1 (https=) |
| MA (1) | MA55958A (https=) |
| MX (1) | MX2021013899A (https=) |
| TW (2) | TWI881977B (https=) |
| WO (1) | WO2020232037A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250006380A (ko) | 2023-07-03 | 2025-01-13 | 연세대학교 산학협력단 | 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| DK2007396T3 (da) | 2006-04-03 | 2013-03-18 | Merck Sharp & Dohme | Enfumafungin-derivat som antimykotika |
| RS53731B1 (sr) * | 2008-08-12 | 2015-06-30 | Scynexis, Inc. | Antigljivični agensi |
| US8188085B2 (en) | 2008-08-12 | 2012-05-29 | Merck Sharp & Dohme Corp. | Antifungal agents |
| WO2017161016A1 (en) * | 2016-03-16 | 2017-09-21 | Cidara Therapeutics, Inc. | Dosing regimens for treatment of fungal infections |
| EP3609539A1 (en) * | 2017-04-10 | 2020-02-19 | Scynexis, Inc. | Antifungal agents used in combination |
| US20200291488A1 (en) | 2017-05-17 | 2020-09-17 | T2 Biosystems, Inc. | Nmr methods and systems for the rapid detection of candida species |
| EP4732902A2 (en) * | 2017-08-04 | 2026-04-29 | Scynexis, Inc. | Antifungal agents with enhanced activity in acidic ph |
| MA54866A (fr) * | 2019-01-30 | 2022-05-04 | Scynexis Inc | Antifongiques triterpénoïdes pour le traitement d'infections ostéoarticulaires fongiques |
-
2020
- 2020-05-12 BR BR112021022876A patent/BR112021022876A2/pt unknown
- 2020-05-12 WO PCT/US2020/032547 patent/WO2020232037A1/en not_active Ceased
- 2020-05-12 EA EA202193146A patent/EA202193146A1/ru unknown
- 2020-05-12 US US17/610,440 patent/US20220211684A1/en active Pending
- 2020-05-12 JP JP2021568113A patent/JP7770191B2/ja active Active
- 2020-05-12 CN CN202080041224.0A patent/CN113905733A/zh active Pending
- 2020-05-12 CA CA3140637A patent/CA3140637A1/en active Pending
- 2020-05-12 EP EP20728876.2A patent/EP3968986A1/en active Pending
- 2020-05-12 MX MX2021013899A patent/MX2021013899A/es unknown
- 2020-05-12 MA MA055958A patent/MA55958A/fr unknown
- 2020-05-12 AU AU2020276595A patent/AU2020276595B2/en active Active
- 2020-05-12 KR KR1020217040747A patent/KR20220009416A/ko active Pending
- 2020-05-15 TW TW109116151A patent/TWI881977B/zh active
- 2020-05-15 TW TW114112703A patent/TW202602460A/zh unknown
-
2021
- 2021-11-16 IL IL288165A patent/IL288165B1/en unknown
-
2025
- 2025-05-02 JP JP2025076668A patent/JP2025118765A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| TWI881977B (zh) | 2025-05-01 |
| US20220211684A1 (en) | 2022-07-07 |
| KR20220009416A (ko) | 2022-01-24 |
| JP2022532734A (ja) | 2022-07-19 |
| TW202602460A (zh) | 2026-01-16 |
| MX2021013899A (es) | 2022-02-10 |
| EA202193146A1 (ru) | 2022-02-11 |
| IL288165A (en) | 2022-01-01 |
| JP2025118765A (ja) | 2025-08-13 |
| EP3968986A1 (en) | 2022-03-23 |
| CN113905733A (zh) | 2022-01-07 |
| AU2020276595A1 (en) | 2021-12-09 |
| TW202110441A (zh) | 2021-03-16 |
| JP7770191B2 (ja) | 2025-11-14 |
| IL288165B1 (en) | 2026-01-01 |
| AU2020276595B2 (en) | 2025-12-04 |
| MA55958A (fr) | 2022-03-23 |
| WO2020232037A1 (en) | 2020-11-19 |
| CA3140637A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| BR112023020442A2 (pt) | Inibidor da protease 1 específica de ubiquitina (usp1) | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| BR112022002720A2 (pt) | Formulações de conjugados de benzazepinas e usos das mesmas | |
| MX2023001963A (es) | Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino. | |
| ZA202210530B (en) | Personal care compositions | |
| BR112017026294A2 (pt) | formulação em gel tópica farmacêutica, e, método para tratar ou prevenir uma doença ou condição. | |
| AR112482A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry | |
| MX2023003448A (es) | Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma. | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| WO2023081830A3 (en) | Compositions and treatments with nirogacestat | |
| WO2022099187A3 (en) | Sars-cov-2 antigen-binding proteins and uses thereof | |
| BR112022010441A2 (pt) | Análogos de equinocandina e método de preparação para os mesmos | |
| CL2025002366A1 (es) | Compuesto que contiene trifluorometilsulfonilo. | |
| WO2023196978A3 (en) | Myc program as a marker of response to enzalutamide in prostate | |
| BR112021022876A2 (pt) | Método para descolonizar candida auris de uma área anatômica de um sujeito | |
| MX2024001313A (es) | Tratamiento del cancer con combinaciones de espironolactona y acilfulvenos. | |
| BR112023006312A2 (pt) | Composto, métodos para preparar o composto, composição farmacêutica e uso do composto | |
| BR112022019338A2 (pt) | Tratamento preventivo de enxaqueca | |
| BR102020012866A8 (pt) | Composições tópicas contendo derivados de n-acil-dipeptídeo e ácido glicólico | |
| DOP2021000215A (es) | Tratamiento de la cefalea usando anticuerpo anti-cgrp |